Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis is under clinical development by NuNerve and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis overview
Fusion protein is under development for the treatment of motor neuron diseases, amyotrophic lateral sclerosis, acute spinal cord injury and ischemia-reperfusion injury. It is administered through intravenous route as infusion. It acts by targeting the protein EphA4. It was under development for the treatment of sepsis.
For a complete picture of Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.